Trials / Withdrawn
WithdrawnNCT01791426
A Study to Evaluate the Performance and Safety of Artelac Rebalance® Versus Vismed in the Management of Dry Eye
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Bausch & Lomb Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this investigation is to show that the performance of Artelac Rebalance eye drops is non-inferior to that of Vismed eye drops in subjects with moderate to severe dry eye, and to assess the safety of Artelac Rebalance after a 90-day (± 10 day) treatment administered 3 to 5 times per day.
Detailed description
Artelac Rebalance and Vismed are in compliance with European Directives (CE marked) products in the European Union (EU).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Artelac Rebalance | Instill 1 drop of the Artelac Rebalance eye drops in each eye 3 to 5 times per day for 90(± 10) day treatment. |
| DEVICE | Vismed | Instill 1 drop of the Vismed eye drops in each eye 3 to 5 times per day for 90(± 10) day treatment. |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2013-10-01
- Completion
- 2013-10-01
- First posted
- 2013-02-15
- Last updated
- 2013-10-11
Source: ClinicalTrials.gov record NCT01791426. Inclusion in this directory is not an endorsement.